Identification of IDH1/2 (IDH) mutation and/or TERT promoter (pTERT) mutation is crucial for reaching a correct diagnosis and choosing the most appropriate treatment for patients harboring WHO grade II/III gliomas. This evidence concerns the gene TERT and glioma.